{"entity":{"type":"insider","cik":"0001721035","url":"/insider/0001721035","json_url":"/insider/0001721035.json","name":"MPM Oncology Impact Management GP LLC","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":76,"n_filings":24,"first":"2017-11-06","last":"2021-08-25","span_basis":"filed_date"},"name_variants":[{"name":"MPM Oncology Impact Management GP LLC","source":"filing","n_filings":24,"first_seen":"2017-11-06","last_seen":"2021-08-25"}],"transactions":[{"id":4342327,"accession":"0001209191-21-053380","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-21-053380","line_url":"/filing/0001209191-21-053380#line-3","is_derivative":false,"issuer_cik":"0001687078","issuer_name":"Cullinan Oncology, Inc.","issuer_ticker":"CGEM","issuer_name_source":null,"issuer_url":"/issuer/0001687078","owner_cik":null,"owner_name":"MPM Oncology Impact Management GP LLC; Oncology Impact Fund (Cayman) Management L.P.; UBS Oncology Impact Fund L.P.; MPM Oncology Impact Management LP","owner_display_name":"MPM Oncology Impact Management GP LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1713.0,"shares_display":"1,713","price_per_share":29.09,"price_display":"29.09","price_state":"stated","total_value":49831.17,"total_display":"49,831.17","total_whole":"49,831","shares_owned_after":7805483.0,"shares_owned_after_display":"7,805,483","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-08-25","filed_date":"2021-08-25","scope":"insider"},{"id":4342324,"accession":"0001209191-21-053380","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-053380","line_url":"/filing/0001209191-21-053380#line-2","is_derivative":false,"issuer_cik":"0001687078","issuer_name":"Cullinan Oncology, Inc.","issuer_ticker":"CGEM","issuer_name_source":null,"issuer_url":"/issuer/0001687078","owner_cik":null,"owner_name":"MPM Oncology Impact Management GP LLC; Oncology Impact Fund (Cayman) Management L.P.; UBS Oncology Impact Fund L.P.; MPM Oncology Impact Management LP","owner_display_name":"MPM Oncology Impact Management GP LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":50822.0,"shares_display":"50,822","price_per_share":29.48,"price_display":"29.48","price_state":"stated","total_value":1498232.56,"total_display":"1,498,232.56","total_whole":"1,498,233","shares_owned_after":7807196.0,"shares_owned_after_display":"7,807,196","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-08-24","filed_date":"2021-08-25","scope":"insider"},{"id":4342321,"accession":"0001209191-21-053380","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-053380","line_url":"/filing/0001209191-21-053380#line-1","is_derivative":false,"issuer_cik":"0001687078","issuer_name":"Cullinan Oncology, Inc.","issuer_ticker":"CGEM","issuer_name_source":null,"issuer_url":"/issuer/0001687078","owner_cik":null,"owner_name":"MPM Oncology Impact Management GP LLC; Oncology Impact Fund (Cayman) Management L.P.; UBS Oncology Impact Fund L.P.; MPM Oncology Impact Management LP","owner_display_name":"MPM Oncology Impact Management GP LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":53359.0,"shares_display":"53,359","price_per_share":29.11,"price_display":"29.11","price_state":"stated","total_value":1553280.49,"total_display":"1,553,280.49","total_whole":"1,553,280","shares_owned_after":7858018.0,"shares_owned_after_display":"7,858,018","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-08-23","filed_date":"2021-08-25","scope":"insider"},{"id":4275886,"accession":"0001209191-21-051148","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-051148","line_url":"/filing/0001209191-21-051148#line-1","is_derivative":false,"issuer_cik":"0001687078","issuer_name":"Cullinan Oncology, Inc.","issuer_ticker":"CGEM","issuer_name_source":null,"issuer_url":"/issuer/0001687078","owner_cik":null,"owner_name":"Oncology Impact Fund (Cayman) Management L.P.; MPM Oncology Impact Management GP LLC; MPM Oncology Impact Management LP; UBS Oncology Impact Fund L.P.","owner_display_name":"Oncology Impact Fund (Cayman) Management L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2510.0,"shares_display":"2,510","price_per_share":29.05,"price_display":"29.05","price_state":"stated","total_value":72915.5,"total_display":"72,915.50","total_whole":"72,916","shares_owned_after":7911377.0,"shares_owned_after_display":"7,911,377","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-08-11","filed_date":"2021-08-12","scope":"insider"},{"id":4227530,"accession":"0001209191-21-037379","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-21-037379","line_url":"/filing/0001209191-21-037379#line-5","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Harpoon Therapeutics, Inc.","issuer_ticker":"HARP","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"MPM Oncology Impact Management GP LLC; Oncology Impact Fund (Cayman) Management L.P.; GADICKE ANSBERT; MPM Oncology Impact Management LP; UBS Oncology Impact Fund L.P.","owner_display_name":"MPM Oncology Impact Management GP LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25118.0,"shares_display":"25,118","price_per_share":20.5,"price_display":"20.50","price_state":"stated","total_value":514919.0,"total_display":"514,919.00","total_whole":"514,919","shares_owned_after":6328095.0,"shares_owned_after_display":"6,328,095","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-06-02","filed_date":"2021-06-02","scope":"insider"},{"id":4227518,"accession":"0001209191-21-037379","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-21-037379","line_url":"/filing/0001209191-21-037379#line-4","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Harpoon Therapeutics, Inc.","issuer_ticker":"HARP","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"MPM Oncology Impact Management GP LLC; Oncology Impact Fund (Cayman) Management L.P.; GADICKE ANSBERT; MPM Oncology Impact Management LP; UBS Oncology Impact Fund L.P.","owner_display_name":"MPM Oncology Impact Management GP LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":18491.0,"shares_display":"18,491","price_per_share":20.44,"price_display":"20.44","price_state":"stated","total_value":377956.04,"total_display":"377,956.04","total_whole":"377,956","shares_owned_after":6353213.0,"shares_owned_after_display":"6,353,213","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-06-01","filed_date":"2021-06-02","scope":"insider"},{"id":4227513,"accession":"0001209191-21-037379","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-21-037379","line_url":"/filing/0001209191-21-037379","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Harpoon Therapeutics, Inc.","issuer_ticker":"HARP","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"MPM Oncology Impact Management GP LLC; Oncology Impact Fund (Cayman) Management L.P.; GADICKE ANSBERT; MPM Oncology Impact Management LP; UBS Oncology Impact Fund L.P.","owner_display_name":"MPM Oncology Impact Management GP LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13885.0,"shares_display":"13,885","price_per_share":21.12458048253511,"price_display":"21.12","price_state":"stated","total_value":293314.8,"total_display":"293,314.80","total_whole":"293,315","shares_owned_after":6374904.0,"shares_owned_after_display":"6,374,904","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-05-28","filed_date":"2021-06-02","scope":"insider","n_lines":3},{"id":4997875,"accession":"0001209191-21-036349","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-036349","line_url":"/filing/0001209191-21-036349#line-2","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Harpoon Therapeutics, Inc.","issuer_ticker":"HARP","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"Oncology Impact Fund (Cayman) Management L.P.; GADICKE ANSBERT; MPM Oncology Impact Management LP; MPM Oncology Impact Management GP LLC; UBS Oncology Impact Fund L.P.","owner_display_name":"Oncology Impact Fund (Cayman) Management L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13961.0,"shares_display":"13,961","price_per_share":20.26,"price_display":"20.26","price_state":"stated","total_value":282849.86,"total_display":"282,849.86","total_whole":"282,850","shares_owned_after":6385589.0,"shares_owned_after_display":"6,385,589","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-05-27","filed_date":"2021-05-27","scope":"insider"},{"id":4997868,"accession":"0001209191-21-036349","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-036349","line_url":"/filing/0001209191-21-036349#line-1","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Harpoon Therapeutics, Inc.","issuer_ticker":"HARP","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"Oncology Impact Fund (Cayman) Management L.P.; GADICKE ANSBERT; MPM Oncology Impact Management LP; MPM Oncology Impact Management GP LLC; UBS Oncology Impact Fund L.P.","owner_display_name":"Oncology Impact Fund (Cayman) Management L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3198.0,"shares_display":"3,198","price_per_share":20.04,"price_display":"20.04","price_state":"stated","total_value":64087.92,"total_display":"64,087.92","total_whole":"64,088","shares_owned_after":6399550.0,"shares_owned_after_display":"6,399,550","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-05-26","filed_date":"2021-05-27","scope":"insider"},{"id":5292162,"accession":"0001209191-21-035558","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-035558","line_url":"/filing/0001209191-21-035558#line-2","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Harpoon Therapeutics, Inc.","issuer_ticker":"HARP","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"MPM Oncology Impact Management LP; GADICKE ANSBERT; MPM Oncology Impact Management GP LLC; Oncology Impact Fund (Cayman) Management L.P.; UBS Oncology Impact Fund L.P.","owner_display_name":"MPM Oncology Impact Management LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":20.12,"price_display":"20.12","price_state":"stated","total_value":100600.0,"total_display":"100,600.00","total_whole":"100,600","shares_owned_after":6402748.0,"shares_owned_after_display":"6,402,748","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-05-24","filed_date":"2021-05-24","scope":"insider"},{"id":5292158,"accession":"0001209191-21-035558","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-035558","line_url":"/filing/0001209191-21-035558#line-1","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Harpoon Therapeutics, Inc.","issuer_ticker":"HARP","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"MPM Oncology Impact Management LP; GADICKE ANSBERT; MPM Oncology Impact Management GP LLC; Oncology Impact Fund (Cayman) Management L.P.; UBS Oncology Impact Fund L.P.","owner_display_name":"MPM Oncology Impact Management LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10907.0,"shares_display":"10,907","price_per_share":20.21,"price_display":"20.21","price_state":"stated","total_value":220430.47,"total_display":"220,430.47","total_whole":"220,430","shares_owned_after":6407748.0,"shares_owned_after_display":"6,407,748","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-05-21","filed_date":"2021-05-24","scope":"insider"},{"id":5428286,"accession":"0001209191-21-034626","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-21-034626","line_url":"/filing/0001209191-21-034626#line-3","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Harpoon Therapeutics, Inc.","issuer_ticker":"HARP","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"MPM Oncology Impact Management GP LLC; GADICKE ANSBERT; MPM Oncology Impact Management LP; UBS Oncology Impact Fund L.P.; Oncology Impact Fund (Cayman) Management L.P.","owner_display_name":"MPM Oncology Impact Management GP LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11713.0,"shares_display":"11,713","price_per_share":20.34,"price_display":"20.34","price_state":"stated","total_value":238242.42,"total_display":"238,242.42","total_whole":"238,242","shares_owned_after":6418655.0,"shares_owned_after_display":"6,418,655","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-05-20","filed_date":"2021-05-20","scope":"insider"},{"id":5428282,"accession":"0001209191-21-034626","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-034626","line_url":"/filing/0001209191-21-034626#line-2","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Harpoon Therapeutics, Inc.","issuer_ticker":"HARP","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"MPM Oncology Impact Management GP LLC; GADICKE ANSBERT; MPM Oncology Impact Management LP; UBS Oncology Impact Fund L.P.; Oncology Impact Fund (Cayman) Management L.P.","owner_display_name":"MPM Oncology Impact Management GP LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":17833.0,"shares_display":"17,833","price_per_share":20.39,"price_display":"20.39","price_state":"stated","total_value":363614.87,"total_display":"363,614.87","total_whole":"363,615","shares_owned_after":6430368.0,"shares_owned_after_display":"6,430,368","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-05-19","filed_date":"2021-05-20","scope":"insider"},{"id":5428279,"accession":"0001209191-21-034626","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-034626","line_url":"/filing/0001209191-21-034626#line-1","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Harpoon Therapeutics, Inc.","issuer_ticker":"HARP","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"MPM Oncology Impact Management GP LLC; GADICKE ANSBERT; MPM Oncology Impact Management LP; UBS Oncology Impact Fund L.P.; Oncology Impact Fund (Cayman) Management L.P.","owner_display_name":"MPM Oncology Impact Management GP LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":18402.0,"shares_display":"18,402","price_per_share":20.67,"price_display":"20.67","price_state":"stated","total_value":380369.34,"total_display":"380,369.34","total_whole":"380,369","shares_owned_after":6448201.0,"shares_owned_after_display":"6,448,201","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-05-18","filed_date":"2021-05-20","scope":"insider"},{"id":4621257,"accession":"0001209191-21-033213","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-21-033213","line_url":"/filing/0001209191-21-033213#line-3","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Harpoon Therapeutics, Inc.","issuer_ticker":"HARP","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"MPM Oncology Impact Management GP LLC; MPM Oncology Impact Management LP; UBS Oncology Impact Fund L.P.; Oncology Impact Fund (Cayman) Management L.P.; GADICKE ANSBERT","owner_display_name":"MPM Oncology Impact Management GP LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4666.0,"shares_display":"4,666","price_per_share":20.07,"price_display":"20.07","price_state":"stated","total_value":93646.62,"total_display":"93,646.62","total_whole":"93,647","shares_owned_after":6466603.0,"shares_owned_after_display":"6,466,603","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-05-17","filed_date":"2021-05-17","scope":"insider"},{"id":4621254,"accession":"0001209191-21-033213","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-033213","line_url":"/filing/0001209191-21-033213#line-2","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Harpoon Therapeutics, Inc.","issuer_ticker":"HARP","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"MPM Oncology Impact Management GP LLC; MPM Oncology Impact Management LP; UBS Oncology Impact Fund L.P.; Oncology Impact Fund (Cayman) Management L.P.; GADICKE ANSBERT","owner_display_name":"MPM Oncology Impact Management GP LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6900.0,"shares_display":"6,900","price_per_share":20.04,"price_display":"20.04","price_state":"stated","total_value":138276.0,"total_display":"138,276.00","total_whole":"138,276","shares_owned_after":6471269.0,"shares_owned_after_display":"6,471,269","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-05-14","filed_date":"2021-05-17","scope":"insider"},{"id":4621249,"accession":"0001209191-21-033213","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-033213","line_url":"/filing/0001209191-21-033213#line-1","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Harpoon Therapeutics, Inc.","issuer_ticker":"HARP","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"MPM Oncology Impact Management GP LLC; MPM Oncology Impact Management LP; UBS Oncology Impact Fund L.P.; Oncology Impact Fund (Cayman) Management L.P.; GADICKE ANSBERT","owner_display_name":"MPM Oncology Impact Management GP LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4855.0,"shares_display":"4,855","price_per_share":20.06,"price_display":"20.06","price_state":"stated","total_value":97391.3,"total_display":"97,391.30","total_whole":"97,391","shares_owned_after":6478169.0,"shares_owned_after_display":"6,478,169","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-05-13","filed_date":"2021-05-17","scope":"insider"},{"id":4483013,"accession":"0001209191-21-032178","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-21-032178","line_url":"/filing/0001209191-21-032178#line-5","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Harpoon Therapeutics, Inc.","issuer_ticker":"HARP","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"MPM Oncology Impact Management GP LLC; UBS Oncology Impact Fund L.P.; GADICKE ANSBERT; MPM Oncology Impact Management LP; Oncology Impact Fund (Cayman) Management L.P.","owner_display_name":"MPM Oncology Impact Management GP LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":29684.0,"shares_display":"29,684","price_per_share":20.53,"price_display":"20.53","price_state":"stated","total_value":609412.52,"total_display":"609,412.52","total_whole":"609,413","shares_owned_after":6483024.0,"shares_owned_after_display":"6,483,024","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-05-12","filed_date":"2021-05-12","scope":"insider"},{"id":4483008,"accession":"0001209191-21-032178","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-21-032178","line_url":"/filing/0001209191-21-032178","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Harpoon Therapeutics, Inc.","issuer_ticker":"HARP","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"MPM Oncology Impact Management GP LLC; UBS Oncology Impact Fund L.P.; GADICKE ANSBERT; MPM Oncology Impact Management LP; Oncology Impact Fund (Cayman) Management L.P.","owner_display_name":"MPM Oncology Impact Management GP LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":21445.0,"shares_display":"21,445","price_per_share":21.156763814408954,"price_display":"21.16","price_state":"stated","total_value":453706.8,"total_display":"453,706.80","total_whole":"453,707","shares_owned_after":6520380.0,"shares_owned_after_display":"6,520,380","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-05-11","filed_date":"2021-05-12","scope":"insider","n_lines":2},{"id":4482999,"accession":"0001209191-21-032178","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-032178","line_url":"/filing/0001209191-21-032178","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Harpoon Therapeutics, Inc.","issuer_ticker":"HARP","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"MPM Oncology Impact Management GP LLC; UBS Oncology Impact Fund L.P.; GADICKE ANSBERT; MPM Oncology Impact Management LP; Oncology Impact Fund (Cayman) Management L.P.","owner_display_name":"MPM Oncology Impact Management GP LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":17133.0,"shares_display":"17,133","price_per_share":21.796312379618282,"price_display":"21.80","price_state":"stated","total_value":373436.22,"total_display":"373,436.22","total_whole":"373,436","shares_owned_after":6534564.0,"shares_owned_after_display":"6,534,564","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-05-10","filed_date":"2021-05-12","scope":"insider","n_lines":2},{"id":4892378,"accession":"0001209191-21-030611","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-030611","line_url":"/filing/0001209191-21-030611","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Harpoon Therapeutics, Inc.","issuer_ticker":"HARP","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"MPM Oncology Impact Management GP LLC; MPM Oncology Impact Management LP; Oncology Impact Fund (Cayman) Management L.P.; UBS Oncology Impact Fund L.P.; GADICKE ANSBERT","owner_display_name":"MPM Oncology Impact Management GP LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10172.0,"shares_display":"10,172","price_per_share":22.523306134486827,"price_display":"22.52","price_state":"stated","total_value":229107.07,"total_display":"229,107.07","total_whole":"229,107","shares_owned_after":6551345.0,"shares_owned_after_display":"6,551,345","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-05-05","filed_date":"2021-05-06","scope":"insider","n_lines":2},{"id":5490784,"accession":"0001209191-21-030625","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-21-030625","line_url":"/filing/0001209191-21-030625#line-3","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Werewolf Therapeutics, Inc.","issuer_ticker":"HOWL","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"MPM Oncology Innovations Fund GP LLC; UBS Oncology Impact Fund L.P.; MPM ONCOLOGY INNOVATIONS FUND LP; GADICKE ANSBERT; MPM Oncology Impact Management LP; MPM Oncology Impact Management GP LLC; Oncology Impact Fund (Cayman) Management L.P.","owner_display_name":"MPM Oncology Innovations Fund GP LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":245000.0,"shares_display":"245,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":3920000.0,"total_display":"3,920,000.00","total_whole":"3,920,000","shares_owned_after":6672183.0,"shares_owned_after_display":"6,672,183","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-05-04","filed_date":"2021-05-06","scope":"insider"},{"id":4667183,"accession":"0001209191-21-029994","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-21-029994","line_url":"/filing/0001209191-21-029994","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Harpoon Therapeutics, Inc.","issuer_ticker":"HARP","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"Oncology Impact Fund (Cayman) Management L.P.; MPM Oncology Impact Management GP LLC; GADICKE ANSBERT; MPM Oncology Impact Management LP; UBS Oncology Impact Fund L.P.","owner_display_name":"Oncology Impact Fund (Cayman) Management L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":29730.0,"shares_display":"29,730","price_per_share":23.06531786074672,"price_display":"23.07","price_state":"stated","total_value":685731.9,"total_display":"685,731.90","total_whole":"685,732","shares_owned_after":6564958.0,"shares_owned_after_display":"6,564,958","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-05-04","filed_date":"2021-05-04","scope":"insider","n_lines":2},{"id":4667176,"accession":"0001209191-21-029994","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-21-029994","line_url":"/filing/0001209191-21-029994","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Harpoon Therapeutics, Inc.","issuer_ticker":"HARP","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"Oncology Impact Fund (Cayman) Management L.P.; MPM Oncology Impact Management GP LLC; GADICKE ANSBERT; MPM Oncology Impact Management LP; UBS Oncology Impact Fund L.P.","owner_display_name":"Oncology Impact Fund (Cayman) Management L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":30766.0,"shares_display":"30,766","price_per_share":23.09007995839563,"price_display":"23.09","price_state":"stated","total_value":710389.4,"total_display":"710,389.40","total_whole":"710,389","shares_owned_after":6595589.0,"shares_owned_after_display":"6,595,589","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-05-03","filed_date":"2021-05-04","scope":"insider","n_lines":2},{"id":4667169,"accession":"0001209191-21-029994","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-029994","line_url":"/filing/0001209191-21-029994#line-1","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Harpoon Therapeutics, Inc.","issuer_ticker":"HARP","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"Oncology Impact Fund (Cayman) Management L.P.; MPM Oncology Impact Management GP LLC; GADICKE ANSBERT; MPM Oncology Impact Management LP; UBS Oncology Impact Fund L.P.","owner_display_name":"Oncology Impact Fund (Cayman) Management L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":268023.0,"shares_display":"268,023","price_per_share":22.35,"price_display":"22.35","price_state":"stated","total_value":5990314.05,"total_display":"5,990,314.05","total_whole":"5,990,314","shares_owned_after":6621954.0,"shares_owned_after_display":"6,621,954","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-04-30","filed_date":"2021-05-04","scope":"insider"},{"id":5379914,"accession":"0001209191-21-029064","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-21-029064","line_url":"/filing/0001209191-21-029064","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Harpoon Therapeutics, Inc.","issuer_ticker":"HARP","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"Oncology Impact Fund (Cayman) Management L.P.; MPM Oncology Impact Management GP LLC; UBS Oncology Impact Fund L.P.; MPM Oncology Impact Management LP; GADICKE ANSBERT","owner_display_name":"Oncology Impact Fund (Cayman) Management L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":67292.0,"shares_display":"67,292","price_per_share":22.188313023836415,"price_display":"22.19","price_state":"stated","total_value":1493095.96,"total_display":"1,493,095.96","total_whole":"1,493,096","shares_owned_after":6911758.0,"shares_owned_after_display":"6,911,758","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-04-29","filed_date":"2021-04-29","scope":"insider","n_lines":2},{"id":5379909,"accession":"0001209191-21-029064","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-21-029064","line_url":"/filing/0001209191-21-029064","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Harpoon Therapeutics, Inc.","issuer_ticker":"HARP","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"Oncology Impact Fund (Cayman) Management L.P.; MPM Oncology Impact Management GP LLC; UBS Oncology Impact Fund L.P.; MPM Oncology Impact Management LP; GADICKE ANSBERT","owner_display_name":"Oncology Impact Fund (Cayman) Management L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":51022.0,"shares_display":"51,022","price_per_share":21.90688702912469,"price_display":"21.91","price_state":"stated","total_value":1117733.19,"total_display":"1,117,733.19","total_whole":"1,117,733","shares_owned_after":6957269.0,"shares_owned_after_display":"6,957,269","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-04-28","filed_date":"2021-04-29","scope":"insider","n_lines":2},{"id":5379906,"accession":"0001209191-21-029064","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-029064","line_url":"/filing/0001209191-21-029064","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Harpoon Therapeutics, Inc.","issuer_ticker":"HARP","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"Oncology Impact Fund (Cayman) Management L.P.; MPM Oncology Impact Management GP LLC; UBS Oncology Impact Fund L.P.; MPM Oncology Impact Management LP; GADICKE ANSBERT","owner_display_name":"Oncology Impact Fund (Cayman) Management L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11829.0,"shares_display":"11,829","price_per_share":21.18008876489982,"price_display":"21.18","price_state":"stated","total_value":250539.27,"total_display":"250,539.27","total_whole":"250,539","shares_owned_after":7008291.0,"shares_owned_after_display":"7,008,291","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-04-27","filed_date":"2021-04-29","scope":"insider","n_lines":2},{"id":4728253,"accession":"0001209191-21-027939","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-027939","line_url":"/filing/0001209191-21-027939","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Harpoon Therapeutics, Inc.","issuer_ticker":"HARP","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"GADICKE ANSBERT; MPM Oncology Impact Management GP LLC; UBS Oncology Impact Fund L.P.; MPM Oncology Impact Management LP; Oncology Impact Fund (Cayman) Management L.P.","owner_display_name":"GADICKE ANSBERT","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8972.0,"shares_display":"8,972","price_per_share":18.973403923316987,"price_display":"18.97","price_state":"stated","total_value":170229.38,"total_display":"170,229.38","total_whole":"170,229","shares_owned_after":7020675.0,"shares_owned_after_display":"7,020,675","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-04-21","filed_date":"2021-04-22","scope":"insider","n_lines":2},{"id":4569386,"accession":"0001209191-21-027611","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-21-027611","line_url":"/filing/0001209191-21-027611","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Harpoon Therapeutics, Inc.","issuer_ticker":"HARP","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"MPM Oncology Impact Management LP; MPM Oncology Impact Management GP LLC; UBS Oncology Impact Fund L.P.; GADICKE ANSBERT; Oncology Impact Fund (Cayman) Management L.P.","owner_display_name":"MPM Oncology Impact Management LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":22249.0,"shares_display":"22,249","price_per_share":18.714619084003775,"price_display":"18.71","price_state":"stated","total_value":416381.56,"total_display":"416,381.56","total_whole":"416,382","shares_owned_after":7029926.0,"shares_owned_after_display":"7,029,926","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-04-20","filed_date":"2021-04-20","scope":"insider","n_lines":2},{"id":4569377,"accession":"0001209191-21-027611","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-21-027611","line_url":"/filing/0001209191-21-027611","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Harpoon Therapeutics, Inc.","issuer_ticker":"HARP","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"MPM Oncology Impact Management LP; MPM Oncology Impact Management GP LLC; UBS Oncology Impact Fund L.P.; GADICKE ANSBERT; Oncology Impact Fund (Cayman) Management L.P.","owner_display_name":"MPM Oncology Impact Management LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10056.0,"shares_display":"10,056","price_per_share":19.29785600636436,"price_display":"19.30","price_state":"stated","total_value":194059.24,"total_display":"194,059.24","total_whole":"194,059","shares_owned_after":7051441.0,"shares_owned_after_display":"7,051,441","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-04-19","filed_date":"2021-04-20","scope":"insider","n_lines":2},{"id":4569369,"accession":"0001209191-21-027611","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-027611","line_url":"/filing/0001209191-21-027611","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Harpoon Therapeutics, Inc.","issuer_ticker":"HARP","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"MPM Oncology Impact Management LP; MPM Oncology Impact Management GP LLC; UBS Oncology Impact Fund L.P.; GADICKE ANSBERT; Oncology Impact Fund (Cayman) Management L.P.","owner_display_name":"MPM Oncology Impact Management LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5847.0,"shares_display":"5,847","price_per_share":19.857968188814777,"price_display":"19.86","price_state":"stated","total_value":116109.54,"total_display":"116,109.54","total_whole":"116,110","shares_owned_after":7061697.0,"shares_owned_after_display":"7,061,697","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-04-16","filed_date":"2021-04-20","scope":"insider","n_lines":2},{"id":5246193,"accession":"0001209191-21-026880","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-21-026880","line_url":"/filing/0001209191-21-026880#line-5","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Harpoon Therapeutics, Inc.","issuer_ticker":"HARP","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"UBS Oncology Impact Fund L.P.; MPM Oncology Impact Management GP LLC; Oncology Impact Fund (Cayman) Management L.P.; MPM Oncology Impact Management LP; GADICKE ANSBERT","owner_display_name":"UBS Oncology Impact Fund L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8696.0,"shares_display":"8,696","price_per_share":20.49,"price_display":"20.49","price_state":"stated","total_value":178181.04,"total_display":"178,181.04","total_whole":"178,181","shares_owned_after":7067244.0,"shares_owned_after_display":"7,067,244","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-04-15","filed_date":"2021-04-15","scope":"insider"},{"id":5246189,"accession":"0001209191-21-026880","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-21-026880","line_url":"/filing/0001209191-21-026880","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Harpoon Therapeutics, Inc.","issuer_ticker":"HARP","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"UBS Oncology Impact Fund L.P.; MPM Oncology Impact Management GP LLC; Oncology Impact Fund (Cayman) Management L.P.; MPM Oncology Impact Management LP; GADICKE ANSBERT","owner_display_name":"UBS Oncology Impact Fund L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13806.0,"shares_display":"13,806","price_per_share":20.77422714761698,"price_display":"20.77","price_state":"stated","total_value":286808.98,"total_display":"286,808.98","total_whole":"286,809","shares_owned_after":7075940.0,"shares_owned_after_display":"7,075,940","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-04-14","filed_date":"2021-04-15","scope":"insider","n_lines":2},{"id":5246182,"accession":"0001209191-21-026880","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-026880","line_url":"/filing/0001209191-21-026880#line-2","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Harpoon Therapeutics, Inc.","issuer_ticker":"HARP","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"UBS Oncology Impact Fund L.P.; MPM Oncology Impact Management GP LLC; Oncology Impact Fund (Cayman) Management L.P.; MPM Oncology Impact Management LP; GADICKE ANSBERT","owner_display_name":"UBS Oncology Impact Fund L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13692.0,"shares_display":"13,692","price_per_share":19.35,"price_display":"19.35","price_state":"stated","total_value":264940.2,"total_display":"264,940.20","total_whole":"264,940","shares_owned_after":7092108.0,"shares_owned_after_display":"7,092,108","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-04-13","filed_date":"2021-04-15","scope":"insider"}],"collapsed":true,"next_cursor":"2021-04-13|5246182","ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001789972","name":"Cullinan Oncology, Inc.","url":"/issuer/0001789972","role":"Ten percent owner","n_filings":3,"first_seen":"2021-01-14","last_seen":"2021-08-25"},{"type":"issuer","type_label":"ISSUER","cik":"0001708493","name":"Harpoon Therapeutics, Inc.","url":"/issuer/0001708493","role":"Ten percent owner","n_filings":14,"first_seen":"2019-02-14","last_seen":"2021-06-02"},{"type":"issuer","type_label":"ISSUER","cik":"0001785530","name":"Werewolf Therapeutics, Inc.","url":"/issuer/0001785530","role":"Ten percent owner","n_filings":1,"first_seen":"2021-05-06","last_seen":"2021-05-06"},{"type":"issuer","type_label":"ISSUER","cik":"0001808865","name":"iTeos Therapeutics, Inc.","url":"/issuer/0001808865","role":"Ten percent owner, Other","n_filings":3,"first_seen":"2020-07-30","last_seen":"2021-04-13"},{"type":"issuer","type_label":"ISSUER","cik":"0001671818","name":"Oncorus, Inc.","url":"/issuer/0001671818","role":"Ten percent owner","n_filings":1,"first_seen":"2020-10-08","last_seen":"2020-10-08"},{"type":"issuer","type_label":"ISSUER","cik":"0001750019","name":"TCR2 THERAPEUTICS INC.","url":"/issuer/0001750019","role":"Ten percent owner","n_filings":1,"first_seen":"2019-02-21","last_seen":"2019-02-21"},{"type":"issuer","type_label":"ISSUER","cik":"0001061027","name":"SUNESIS PHARMACEUTICALS INC","url":"/issuer/0001061027","role":"Ten percent owner","n_filings":1,"first_seen":"2017-11-06","last_seen":"2017-11-06"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001721035","retrieved_at":"2026-08-22T08:37:56+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}